-
1
-
-
84906250752
-
Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how
-
J.J. Hornberg et al. Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how Drug Discov. Today 2014 http://dx.doi.org/10. 1016/j.drudis.2013.12.008
-
(2014)
Drug Discov. Today
-
-
Hornberg, J.J.1
-
2
-
-
79958067466
-
Impact and frequency of different toxicities throughout the pharmaceutical life cycle
-
W.S. Redfern et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle Toxicologist 114 2010 1081
-
(2010)
Toxicologist
, vol.114
, pp. 1081
-
-
Redfern, W.S.1
-
3
-
-
3242884869
-
Cardiovascular side effects of new antidepressants and antipsychotics: New drugs, old concerns?
-
P. Pacher, and V. Kecskeméti Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr. Pharm. Des. 10 2004 2463 2475
-
(2004)
Curr. Pharm. Des.
, vol.10
, pp. 2463-2475
-
-
Pacher, P.1
Kecskeméti, V.2
-
4
-
-
33846424247
-
The failure of torcetrapib: Was it the molecule or the mechanism?
-
A.R. Tall et al. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler. Thromb. Vasc. Biol. 27 2007 257 260
-
(2007)
Arterioscler. Thromb. Vasc. Biol.
, vol.27
, pp. 257-260
-
-
Tall, A.R.1
-
5
-
-
73249114314
-
Investigational positive inotropic agents for acute heart failure
-
J. Tamargo et al. Investigational positive inotropic agents for acute heart failure Cardiovasc. Hematol. Disord. Drug Targets 9 2009 193 205
-
(2009)
Cardiovasc. Hematol. Disord. Drug Targets
, vol.9
, pp. 193-205
-
-
Tamargo, J.1
-
6
-
-
74549165352
-
An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk
-
C.E. Pollard et al. An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk Br. J. Pharmacol. 159 2010 12 21
-
(2010)
Br. J. Pharmacol.
, vol.159
, pp. 12-21
-
-
Pollard, C.E.1
-
9
-
-
0344492207
-
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development
-
W.S. Redfern et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development Cardiovasc. Res. 58 2003 32 45
-
(2003)
Cardiovasc. Res.
, vol.58
, pp. 32-45
-
-
Redfern, W.S.1
-
10
-
-
79151474418
-
An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation
-
G. Gintant An evaluation of hERG current assay performance: translating preclinical safety studies to clinical QT prolongation Pharmacol. Ther. 129 2011 109 119
-
(2011)
Pharmacol. Ther.
, vol.129
, pp. 109-119
-
-
Gintant, G.1
-
11
-
-
31044434071
-
The L-type calcium channel in the heart: The beat goes on
-
I. Bodi et al. The L-type calcium channel in the heart: the beat goes on J. Clin. Invest. 115 2005 3306 3317
-
(2005)
J. Clin. Invest.
, vol.115
, pp. 3306-3317
-
-
Bodi, I.1
-
12
-
-
79960999452
-
+ channel and drug-induced prolongation of the QRS complex
-
+ channel and drug-induced prolongation of the QRS complex Br. J. Pharmacol. 164 2011 260 273
-
(2011)
Br. J. Pharmacol.
, vol.164
, pp. 260-273
-
-
Harmer, A.R.1
-
13
-
-
68549109498
-
Blockade of the IKs potassium channel: An overlooked cardiovascular liability in drug safety screening?
-
R. Towart et al. Blockade of the IKs potassium channel: an overlooked cardiovascular liability in drug safety screening? J. Pharmacol. Toxicol. Methods 60 2009 1 10
-
(2009)
J. Pharmacol. Toxicol. Methods
, vol.60
, pp. 1-10
-
-
Towart, R.1
-
14
-
-
79955643815
-
Retrograde heart perfusion: The Langendorff technique of isolated heart perfusion
-
R.M. Bell et al. Retrograde heart perfusion: the Langendorff technique of isolated heart perfusion J. Mol. Cell. Cardiol. 50 2011 940 950
-
(2011)
J. Mol. Cell. Cardiol.
, vol.50
, pp. 940-950
-
-
Bell, R.M.1
-
15
-
-
2542432906
-
Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization
-
B.D. Guth et al. Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization J. Pharmacol. Toxicol. Methods 49 2004 159 169
-
(2004)
J. Pharmacol. Toxicol. Methods
, vol.49
, pp. 159-169
-
-
Guth, B.D.1
-
16
-
-
68549125133
-
The fentanyl/etomidate-anaesthetised beagle (FEAB) dog: A versatile in vivo model in cardiovascular safety research
-
B. Van Deuren et al. The fentanyl/etomidate-anaesthetised beagle (FEAB) dog: a versatile in vivo model in cardiovascular safety research J. Pharmacol. Toxicol. Methods 60 2009 11 23
-
(2009)
J. Pharmacol. Toxicol. Methods
, vol.60
, pp. 11-23
-
-
Van Deuren, B.1
-
17
-
-
20844444779
-
Idiosyncratic drug hepatotoxicity
-
N. Kaplowitz Idiosyncratic drug hepatotoxicity Nat. Rev. Drug Discov. 4 2005 489 499
-
(2005)
Nat. Rev. Drug Discov.
, vol.4
, pp. 489-499
-
-
Kaplowitz, N.1
-
18
-
-
77952718055
-
Risk factors for idiosyncratic drug-induced liver injury
-
N. Chalasani, and E. Bjornsson Risk factors for idiosyncratic drug-induced liver injury Gastroenterology 138 2010 2246 2259
-
(2010)
Gastroenterology
, vol.138
, pp. 2246-2259
-
-
Chalasani, N.1
Bjornsson, E.2
-
19
-
-
78549248177
-
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development
-
R.E. Morgan et al. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development Toxicol. Sci. 118 2010 485 500
-
(2010)
Toxicol. Sci.
, vol.118
, pp. 485-500
-
-
Morgan, R.E.1
-
20
-
-
34248547635
-
MRP2 haplotypes confer differential susceptibility to toxic liver injury
-
J.H. Choi et al. MRP2 haplotypes confer differential susceptibility to toxic liver injury Pharmacogenet. Genomics 17 2007 403 415
-
(2007)
Pharmacogenet. Genomics
, vol.17
, pp. 403-415
-
-
Choi, J.H.1
-
21
-
-
84883187061
-
A high content screening assay to predict human drug-induced liver injury during drug discovery
-
M. Persson et al. A high content screening assay to predict human drug-induced liver injury during drug discovery J. Pharmacol. Toxicol. Methods 68 2013 302 313
-
(2013)
J. Pharmacol. Toxicol. Methods
, vol.68
, pp. 302-313
-
-
Persson, M.1
-
22
-
-
33747084103
-
High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening
-
P.J. O'Brien et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening Arch. Toxicol. 80 2006 580 604
-
(2006)
Arch. Toxicol.
, vol.80
, pp. 580-604
-
-
O'Brien, P.J.1
-
23
-
-
49249103327
-
Cellular imaging predictions of clinical drug-induced liver injury
-
J.J. Xu et al. Cellular imaging predictions of clinical drug-induced liver injury Toxicol. Sci. 105 2008 97 105
-
(2008)
Toxicol. Sci.
, vol.105
, pp. 97-105
-
-
Xu, J.J.1
-
24
-
-
84865208356
-
In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs
-
R.A. Thompson et al. In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs Chem. Res. Toxicol. 25 2012 1616 1632
-
(2012)
Chem. Res. Toxicol.
, vol.25
, pp. 1616-1632
-
-
Thompson, R.A.1
-
25
-
-
84869400376
-
A performance evaluation of three drug-induced liver injury biomarkers in the rat: Alpha-glutathione S-transferase, arginase 1, and 4-hydroxyphenyl- pyruvate dioxygenase
-
W.J. Bailey et al. A performance evaluation of three drug-induced liver injury biomarkers in the rat: alpha-glutathione S-transferase, arginase 1, and 4-hydroxyphenyl-pyruvate dioxygenase Toxicol. Sci. 130 2012 229 244
-
(2012)
Toxicol. Sci.
, vol.130
, pp. 229-244
-
-
Bailey, W.J.1
-
26
-
-
78650561076
-
Application of toxicogenomics in hepatic systems toxicology for risk assessment: Acetaminophen as a case study
-
A.S. Kienhuis et al. Application of toxicogenomics in hepatic systems toxicology for risk assessment: acetaminophen as a case study Toxicol. Appl. Pharmacol. 250 2011 96 107
-
(2011)
Toxicol. Appl. Pharmacol.
, vol.250
, pp. 96-107
-
-
Kienhuis, A.S.1
-
27
-
-
80051727852
-
Predicting drug-induced hepatotoxicity using QSAR and toxicogenomics approaches
-
Y. Low et al. Predicting drug-induced hepatotoxicity using QSAR and toxicogenomics approaches Chem. Res. Toxicol. 24 2011 1251 1262
-
(2011)
Chem. Res. Toxicol.
, vol.24
, pp. 1251-1262
-
-
Low, Y.1
-
28
-
-
79959434611
-
Comparative evaluation of in silico systems for Ames test mutagenicity prediction: Scope and limitations
-
A. Hillebrecht et al. Comparative evaluation of in silico systems for Ames test mutagenicity prediction: scope and limitations Chem. Res. Toxicol. 24 2011 843 854
-
(2011)
Chem. Res. Toxicol.
, vol.24
, pp. 843-854
-
-
Hillebrecht, A.1
-
29
-
-
0032465960
-
Identification of rodent carcinogens and noncarcinogens using genetic toxicity tests: Premises, promises, and performance
-
E. Zeiger Identification of rodent carcinogens and noncarcinogens using genetic toxicity tests: premises, promises, and performance Regul. Toxicol. Pharmacol. 28 1998 85 95
-
(1998)
Regul. Toxicol. Pharmacol.
, vol.28
, pp. 85-95
-
-
Zeiger, E.1
-
30
-
-
84862327553
-
Direct comparison of the Ames microplate format (MPF) test in liquid medium with the standard Ames pre-incubation assay on agar plates by use of equivocal to weakly positive test compounds
-
S. Fluckiger-Isler, and M. Kamber Direct comparison of the Ames microplate format (MPF) test in liquid medium with the standard Ames pre-incubation assay on agar plates by use of equivocal to weakly positive test compounds Mutat. Res. 747 2012 36 45
-
(2012)
Mutat. Res.
, vol.747
, pp. 36-45
-
-
Fluckiger-Isler, S.1
Kamber, M.2
-
31
-
-
0033862929
-
Comparison of the results of a modified miniscreen and the standard bacterial reverse mutation assays
-
M.S. Diehl et al. Comparison of the results of a modified miniscreen and the standard bacterial reverse mutation assays Environ. Mol. Mutagen. 36 2000 72 77
-
(2000)
Environ. Mol. Mutagen.
, vol.36
, pp. 72-77
-
-
Diehl, M.S.1
-
32
-
-
34248525923
-
In vitro micronucleus assay scored by flow cytometry provides a comprehensive evaluation of cytogenetic damage and cytotoxicity
-
S.M. Bryce et al. In vitro micronucleus assay scored by flow cytometry provides a comprehensive evaluation of cytogenetic damage and cytotoxicity Mutat. Res. 630 2007 78 91
-
(2007)
Mutat. Res.
, vol.630
, pp. 78-91
-
-
Bryce, S.M.1
-
33
-
-
79951679077
-
A core in vitro genotoxicity battery comprising the Ames test plus the in vitro micronucleus test is sufficient to detect rodent carcinogens and in vivo genotoxins
-
D. Kirkland et al. A core in vitro genotoxicity battery comprising the Ames test plus the in vitro micronucleus test is sufficient to detect rodent carcinogens and in vivo genotoxins Mutat. Res. 721 2011 27 73
-
(2011)
Mutat. Res.
, vol.721
, pp. 27-73
-
-
Kirkland, D.1
-
34
-
-
77950155012
-
GADD45a-GFP GreenScreen HC assay results for the ECVAM recommended lists of genotoxic and non-genotoxic chemicals for assessment of new genotoxicity tests
-
L. Birrell et al. GADD45a-GFP GreenScreen HC assay results for the ECVAM recommended lists of genotoxic and non-genotoxic chemicals for assessment of new genotoxicity tests Mutat. Res. 695 2010 87 95
-
(2010)
Mutat. Res.
, vol.695
, pp. 87-95
-
-
Birrell, L.1
-
35
-
-
33746309471
-
High-specificity and high-sensitivity genotoxicity assessment in a human cell line: Validation of the GreenScreen HC GADD45a-GFP genotoxicity assay
-
P.W. Hastwell et al. High-specificity and high-sensitivity genotoxicity assessment in a human cell line: validation of the GreenScreen HC GADD45a-GFP genotoxicity assay Mutat. Res. 607 2006 160 175
-
(2006)
Mutat. Res.
, vol.607
, pp. 160-175
-
-
Hastwell, P.W.1
-
36
-
-
84864153864
-
Nongenotoxic apoptosis inducers do not produce misleading positive results in the TK6 cell-based GADD45a-GFP genotoxicity assay
-
C.H. Topham et al. Nongenotoxic apoptosis inducers do not produce misleading positive results in the TK6 cell-based GADD45a-GFP genotoxicity assay Toxicol. Sci. 128 2012 79 91
-
(2012)
Toxicol. Sci.
, vol.128
, pp. 79-91
-
-
Topham, C.H.1
-
37
-
-
0030813923
-
On the metabolizing systems for short-term genotoxicity assays: A review
-
M. Paolini, and G. Cantelli-Forti On the metabolizing systems for short-term genotoxicity assays: a review Mutat. Res. 387 1997 17 34
-
(1997)
Mutat. Res.
, vol.387
, pp. 17-34
-
-
Paolini, M.1
Cantelli-Forti, G.2
-
38
-
-
33847325174
-
How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop
-
D. Kirkland et al. How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: report of an ECVAM Workshop Mutat. Res. 628 2007 31 55
-
(2007)
Mutat. Res.
, vol.628
, pp. 31-55
-
-
Kirkland, D.1
-
39
-
-
84856111701
-
Reduction of misleading (false) positive results in mammalian cell genotoxicity assays. I. Choice of cell type
-
P. Fowler et al. Reduction of misleading (false) positive results in mammalian cell genotoxicity assays. I. Choice of cell type Mutat. Res. 742 2012 11 25
-
(2012)
Mutat. Res.
, vol.742
, pp. 11-25
-
-
Fowler, P.1
-
40
-
-
84862331466
-
Reduction of misleading (false) positive results in mammalian cell genotoxicity assays. II. Importance of accurate toxicity measurement
-
P. Fowler et al. Reduction of misleading (false) positive results in mammalian cell genotoxicity assays. II. Importance of accurate toxicity measurement Mutat. Res. 747 2012 104 117
-
(2012)
Mutat. Res.
, vol.747
, pp. 104-117
-
-
Fowler, P.1
-
41
-
-
78149396570
-
Analysis of published data for top concentration considerations in mammalian cell genotoxicity testing
-
J.M. Parry et al. Analysis of published data for top concentration considerations in mammalian cell genotoxicity testing Mutagenesis 25 2010 531 538
-
(2010)
Mutagenesis
, vol.25
, pp. 531-538
-
-
Parry, J.M.1
-
42
-
-
34249088320
-
An evaluation of the sensitivity of the Ames assay to discern low-level mutagenic impurities
-
M.O. Kenyon et al. An evaluation of the sensitivity of the Ames assay to discern low-level mutagenic impurities Regul. Toxicol. Pharmacol. 48 2007 75 86
-
(2007)
Regul. Toxicol. Pharmacol.
, vol.48
, pp. 75-86
-
-
Kenyon, M.O.1
-
44
-
-
33747103575
-
Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin
-
S. Roychowdhury, and C.K. Svensson Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin AAPS J. 7 2005 E834 E846
-
(2005)
AAPS J.
, vol.7
-
-
Roychowdhury, S.1
Svensson, C.K.2
-
45
-
-
69549117354
-
Drug-induced autoimmunity
-
F. Dedeoglu Drug-induced autoimmunity Curr. Opin. Rheumatol. 21 2009 547 551
-
(2009)
Curr. Opin. Rheumatol.
, vol.21
, pp. 547-551
-
-
Dedeoglu, F.1
-
46
-
-
0032435451
-
Immunotoxicology assessment in the pharmaceutical industry
-
J.H. Dean et al. Immunotoxicology assessment in the pharmaceutical industry Toxicol. Lett. 102-103 1998 247 255
-
(1998)
Toxicol. Lett.
, vol.102-103
, pp. 247-255
-
-
Dean, J.H.1
-
48
-
-
0038144117
-
-
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
-
Anon. Guidance for Industry: Immunotoxicology Evaluation of Investigational New Drugs 2002 U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
-
(2002)
Guidance for Industry: Immunotoxicology Evaluation of Investigational New Drugs
-
-
-
49
-
-
84874295174
-
Methods: Implementation of in vitro and ex vivo phagocytosis and respiratory burst function assessments in safety testing
-
W.J. Freebern et al. Methods: implementation of in vitro and ex vivo phagocytosis and respiratory burst function assessments in safety testing J. Immunotoxicol. 10 2013 106 117
-
(2013)
J. Immunotoxicol.
, vol.10
, pp. 106-117
-
-
Freebern, W.J.1
-
50
-
-
0037394650
-
NK-cell activity in immunotoxicity drug evaluation
-
K. Cederbrant et al. NK-cell activity in immunotoxicity drug evaluation Toxicology 185 2003 241 250
-
(2003)
Toxicology
, vol.185
, pp. 241-250
-
-
Cederbrant, K.1
-
51
-
-
84874311606
-
Evaluation of primary and secondary responses to a T-cell-dependent antigen, keyhole limpet hemocyanin, in rats
-
R. Kawai et al. Evaluation of primary and secondary responses to a T-cell-dependent antigen, keyhole limpet hemocyanin, in rats J. Immunotoxicol. 10 2013 40 48
-
(2013)
J. Immunotoxicol.
, vol.10
, pp. 40-48
-
-
Kawai, R.1
-
52
-
-
84866479621
-
Multiparametric immunotoxicity screening in mice during early drug development
-
M. Auli et al. Multiparametric immunotoxicity screening in mice during early drug development Toxicol. Lett. 214 2012 200 208
-
(2012)
Toxicol. Lett.
, vol.214
, pp. 200-208
-
-
Auli, M.1
-
53
-
-
0033920849
-
Can host resistance assays be used to evaluate the immunotoxicity of pharmaceuticals?
-
D. Wierda Can host resistance assays be used to evaluate the immunotoxicity of pharmaceuticals? Hum. Exp. Toxicol. 19 2000 244 245
-
(2000)
Hum. Exp. Toxicol.
, vol.19
, pp. 244-245
-
-
Wierda, D.1
-
54
-
-
84865625466
-
Safety immunopharmacology: Evaluation of the adverse potential of pharmaceuticals on the immune system
-
J. Descotes Safety immunopharmacology: evaluation of the adverse potential of pharmaceuticals on the immune system J. Pharmacol. Toxicol. Methods 66 2012 79 83
-
(2012)
J. Pharmacol. Toxicol. Methods
, vol.66
, pp. 79-83
-
-
Descotes, J.1
-
55
-
-
68549133165
-
Exploratory drug safety: A discovery strategy to reduce attrition in development
-
A.S. Bass et al. Exploratory drug safety: a discovery strategy to reduce attrition in development J. Pharmacol. Toxicol. Methods 60 2009 69 78
-
(2009)
J. Pharmacol. Toxicol. Methods
, vol.60
, pp. 69-78
-
-
Bass, A.S.1
-
56
-
-
0033771951
-
Concordance of the toxicity of pharmaceuticals in humans and in animals
-
H. Olson et al. Concordance of the toxicity of pharmaceuticals in humans and in animals Regul. Toxicol. Pharmacol. 32 2000 56 67
-
(2000)
Regul. Toxicol. Pharmacol.
, vol.32
, pp. 56-67
-
-
Olson, H.1
-
57
-
-
84879682740
-
Potentials and limitations of nonclinical safety assessment for predicting clinical adverse drug reactions: Correlation analysis of 142 approved drugs in Japan
-
C. Tamaki et al. Potentials and limitations of nonclinical safety assessment for predicting clinical adverse drug reactions: correlation analysis of 142 approved drugs in Japan J. Toxicol. Sci. 38 2013 581 598
-
(2013)
J. Toxicol. Sci.
, vol.38
, pp. 581-598
-
-
Tamaki, C.1
-
58
-
-
0022384250
-
The value of chronic animal toxicology studies of pharmaceutical compounds: A retrospective analysis
-
C.E. Lumley, and S.R. Walker The value of chronic animal toxicology studies of pharmaceutical compounds: a retrospective analysis Fundam. Appl. Toxicol. 5 1985 1007 1024
-
(1985)
Fundam. Appl. Toxicol.
, vol.5
, pp. 1007-1024
-
-
Lumley, C.E.1
Walker, S.R.2
-
59
-
-
84868305913
-
The ability of animal studies to detect serious post marketing adverse events is limited
-
P.J. van Meer et al. The ability of animal studies to detect serious post marketing adverse events is limited Regul. Toxicol. Pharmacol. 64 2012 345 349
-
(2012)
Regul. Toxicol. Pharmacol.
, vol.64
, pp. 345-349
-
-
Van Meer, P.J.1
-
60
-
-
1642282158
-
First dose of potential new medicines to humans: How animals help
-
P. Greaves et al. First dose of potential new medicines to humans: how animals help Nat. Rev. Drug Discov. 3 2004 226 236
-
(2004)
Nat. Rev. Drug Discov.
, vol.3
, pp. 226-236
-
-
Greaves, P.1
-
61
-
-
69749127917
-
Approaches to seizure risk assessment in preclinical drug discovery
-
A. Easter et al. Approaches to seizure risk assessment in preclinical drug discovery Drug Discov. Today 14 2009 876 884
-
(2009)
Drug Discov. Today
, vol.14
, pp. 876-884
-
-
Easter, A.1
-
62
-
-
84255171164
-
Toward in vitro biomarkers for developmental toxicity and their extrapolation to the in vivo situation
-
J. Louisse et al. Toward in vitro biomarkers for developmental toxicity and their extrapolation to the in vivo situation Expert Opin. Drug Metab. Toxicol. 8 2012 11 27
-
(2012)
Expert Opin. Drug Metab. Toxicol.
, vol.8
, pp. 11-27
-
-
Louisse, J.1
-
63
-
-
0025863682
-
Computer prediction of possible toxic action from chemical structure; The DEREK system
-
D.M. Sanderson, and C.G. Earnshaw Computer prediction of possible toxic action from chemical structure; the DEREK system Hum. Exp. Toxicol. 10 1991 261 273
-
(1991)
Hum. Exp. Toxicol.
, vol.10
, pp. 261-273
-
-
Sanderson, D.M.1
Earnshaw, C.G.2
-
64
-
-
80053004364
-
Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: A perspective based on the critical examination of trends in the top 200 drugs marketed in the United States
-
A.F. Stepan et al. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States Chem. Res. Toxicol. 24 2011 1345 1410
-
(2011)
Chem. Res. Toxicol.
, vol.24
, pp. 1345-1410
-
-
Stepan, A.F.1
-
66
-
-
84870774465
-
Reducing safety-related drug attrition: The use of in vitro pharmacological profiling
-
J. Bowes et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling Nat. Rev. Drug Discov. 11 2012 909 922
-
(2012)
Nat. Rev. Drug Discov.
, vol.11
, pp. 909-922
-
-
Bowes, J.1
-
67
-
-
0043031339
-
Predicting ADME properties and side effects: The BioPrint approach
-
C.M. Krejsa et al. Predicting ADME properties and side effects: the BioPrint approach Curr. Opin. Drug Discov. Dev. 6 2003 470 480
-
(2003)
Curr. Opin. Drug Discov. Dev.
, vol.6
, pp. 470-480
-
-
Krejsa, C.M.1
|